A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developability.
Erasmus MF, Bedinger D, Hopkins E, Ferguson G, Strickler J, Graff CP, Summers SR, Capehart SL, Slocum JD, Richardson C, Kumar S, Sun Z, Shang Y, Zhang J, Gu M, Yi L, Wellner A, Zheng S, Lu W, Sormanni P, Greenig M, Zhang H, Mann BT, Baghbanzadeh M, Rahnavard A, Moore GL, Sun H, Ding Y, Nisthal A, Kanodia J, Bernett MJ, Pélissier A, Shao Y, Rodriguez Martinez M, Ramesh K, Nastri H, Evers A, Abdelatif A, Bordner AJ, Bordyuh M, Heo L, Kidd BA, Serhat Tetikol H, Wei S, Shin JE, Peckner R, Manley L, Lunge A, Devasurmutt Y, Guloglu B, Copoiu L, McGibbon M, Fernandez-Quintero ML, Mishra N, Callaghan SM, Swanson OM, Bader DLV, Ferguson JA, Raghavan SSR, Nemoz B, Maillie CA, Bowman C, Briney B, Ward AB, Marcatili P, Akbar R, He B, Wu F, Yao J, Hu B, Kucer M, Gibson KR, Somasundaram R, Hung LW, Kaszuba T, Fremont DH, Jeong H, Kurella VB, Malhotra S, Kumar S, Liu Y, Xu L, Misa J, John ANS, Vogt J, Dávila-Hernández FA, Xu D, Chungyoun M, Huggan ZD, Gray JJ, Parkinson J, Ko YS, Wang W, Geiger F, Ziegler JD, Haas N, Challacombe C, Qamar A, Singh A, Tang YC, An Z, Jiang X, Kim Y, Zhao X, Swanson E, Klattig J, Winkler K, Bataa T, Sandig V, Denzler L, Liu C, Brezski RJ, Spector L, Perea-Schmittle K, D'Angelo S, Ferrara F, Bradbury ARM.
Aug. 19, 2026
